| Two cases of primary CNS lymphoma treated with rituximab and temozolomide |
|
Yoon-Suk Lee, Moo-Jung Kim, Jung-Il Park, Hyun-Woo Lee, Joon-Seong Park, Kyung-Gi Cho, Hugh-Chul Kim |
|
|
| 증례 : 원발성 중추신경계 림프종에서 리툭시맵과 테모졸로미드 병합치료 |
|
이윤석.김무정.박정일.이현우.박준성.조경기.김효철, Moo-Jung Kim, Jung-Il Park, Hyun-Woo Lee, Joon-Seong Park, Kyung-Gi Cho, Hugh-Chul Kim |
|
|
|
|
|
|
| Abstract |
|
Primary CNS lymphoma (PCNSL) is rare, occurring in 2～3% of all non-Hodgkin’s lymphoma. However, in recent years the incidence has increased. To date, the main treatment modalities are radiation therapy, steroids, methotrexate, or combination therapies. The response and overall prognosis remain poor. Use of CHOP in PCNSL has been disappointing in overall response, presumably due to poor penetration through the blood-brain barrier (BBB). We experienced excellent results using a combination of rituximab and the BBB-penetrating alkylating agent temozolomide. Two cases were diagnosed with PCNSL (diffuse large B cell lymphoma) with strong CD 20 positivity. They were placed on a 3-week cycle of rituximab 375 mg/m2 and 5 days of temozolomide 150 mg/m2. After six cycles of chemotherapy, repeat MRIs showed complete remission. Overall, tolerance to chemotherapy was excellent, with no significant marrow suppression. The combination of rituximab and temozolomide may be an effective regimen for the treatment of primary CNS lymphoma. (Korean J Med 75:S806-S810, 2008) |
| Key Words:
Primary central nervous system lymphoma; Rituximab, Temozolomide |
|
PDF Links
Full text via DOI
Download Citation
